Authored by Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi Over the past few decades, progress in understanding the molecular drivers of disease has revealed exciting new […]readmore
Tags : Technologies
Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion […]readmore
Shots: Merck acquires Immune Design, in all stock transaction for $5.85/share in cash making total deal value ~ $300M. The transaction is expected to close in Q2’19 The focus of […]readmore